Potential of nonpeptide (ant)agonists to rescue vasopressin v2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus

Journal of Neuroendocrinology

Volumn 22, Issue 5, 2010, Pages 393-399

  Los, E L ^a   Deen, P M T ^a   Robben, J H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Membrane nuclear; Receptors; Vasopressin

Indexed keywords

CHAPERONE; CONIVAPTAN; HORMONE RECEPTOR STIMULATING AGENT; LIXIVAPTAN; MCF 14; MCF 18; MCF 57; MOZAVAPTAN; OPC 51803; RELCOVAPTAN; SATAVAPTAN; TOLVAPTAN; UNCLASSIFIED DRUG; VA 999088; VA 999089; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR AGONIST; VASOPRESSIN RECEPTOR;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; NEPHROGENIC DIABETES INSIPIDUS; OSMOREGULATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; CELL MEMBRANE PERMEABILITY; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; MUTATION; REVIEW; X CHROMOSOME LINKED DISORDER;

CELL MEMBRANE PERMEABILITY; DIABETES INSIPIDUS, NEPHROGENIC; GENETIC DISEASES, X-LINKED; HUMANS; MUTATION; RECEPTORS, VASOPRESSIN;

EID: 77956119735     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2010.01983.x     Document Type: Article

References (36)

1. Boone M, Deen P. Physiology and pathophysiology of the vasopressinregulated renal water reabsorption. Pflugers Arch 2008; 456: 1005- 1024.
2. Fenton RA, Knepper MA. Mouse models and the urinary concentrating mechanism in the new millennium. Physiol Rev 2007; 87: 1083-1112.
3. Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, van Os CH, van Oost BA. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994; 264: 92-95.
4. Mulders SM, Bichet DG, Rijss JPL, Kamsteeg EJ, Arthus MF, Lonergan M, Fujiwara M, Morgan K, Leijendekker R, van der Sluijs P, van Os CH, Deen PMT. An aquaporin-2 water channel mutant which causes autosomal dominant nephrogenic diabetes insipidus is retained in the Golgi complex. J Clin Invest 1998; 102: 57-66.
5. Van den Ouweland AMW, Dreesen JCFM, Verdijk M, Knoers NVAM, Monnens LAH, Rocchi M, VanOost BA. Mutations in the vasopressin type-2 receptor gene (Avpr2) associated with nephrogenic diabetes-insipidus. Nat Genet 1992; 2: 99-102.
6. Rosenthal W, Seibold A, Antaramian A, Lonergan M, Arthus MF, Hendy GN, Birnbaumer M, Bichet DG. Molecular-identification of the gene responsible for congenital nephrogenic diabetes-insipidus. Nature 1992; 359: 233-235.
7. Bichet DG. Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis 2006; 13: 96-104.
8. Robben JH, Knoers NVAM, Deen PMT. Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2006; 291: F257-F270.
9. Knoers NV, Monnens LL. Nephrogenic diabetes insipidus. Semin Nephrol 1999; 19: 344-352.
10. Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S. Lithiuminduced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest 1995; 95: 1838-1845.
11. Christensen BM, Marples D, Kim YH, Wang W, Frokiaer J, Nielsen S. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol 2004; 286: C952- C964.
12. Shirley DG, Walter SJ, Laycock JF. The antidiuretic effect of chronic hydrochlorothiazide treatment in rats with diabetes insipidus: renal mechanisms. Clin Sci (Lond) 1982; 63: 533-538.
13. Earley LE, Orloff J. The mechanism of antidiuresis associated with the administration of hydrochlorothiazide to patients with vasopressin-resistant diabetes insipidus. J Clin Invest 1962; 41: 1988-1997.
14. Robben JH, Deen PM. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application. Biodrugs 2007; 21: 157-166.
15. Bichet DG. Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol 2008; 28: 245-251.
16. Robben JH, Knoers NVAM, Deen PMT. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model. Am J Physiol Renal Physiol 2005; 289: F265-F272.
17. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, Petaja-Repo U, Angers S, Morin D, Bichet DG, Bouvier M. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000; 105: 887-895.
18. Bernier V, Morello JP, Zarruk A, Debrand N, Salahpour A, Lonergan M, Arthus MF, Laperriere A, Brouard R, Bouvier M, Bichet DG. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2006; 17: 232-243.
19. Wuller S, Wiesner B, Loffler A, Furkert J, Krause G, Hermosilla R, Schaefer M, Schulein R, Rosenthal W, Oksche A. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J Biol Chem 2004; 279: 47254-47263.
20. Hermosilla R, Oueslati M, Donalies U, Schonenberger E, Krause E, Oksche A, Rosenthal W, Schulein R. Disease-causing V2 vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic 2004; 5: 993-1005.
21. Robben JH, Sze M, Knoers NVAM, Deen PMT. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. Mol Biol Cell 2006; 17: 379-386.
22. Oueslati M, Hermosilla R, Schonenberger E, Oorschot V, Beyermann M, Wiesner B, Schmidt A, Klumperman J, Rosenthal W, Schulein R. Rescue of a nephrogenic diabetes insipidus-causing vaospressin V2 receptor mutant by cell-penetrating peptides. J Biol Chem 2007; 282: 20676-20685.
23. Tan CM, Nickols HH, Limbird LE. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation. J Biol Chem 2003; 278: 35678-35686.
24. Bernier V, Lagace M, Lonergan M, Arthus MF, Bichet DG, Bouvier M. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol 2004; 18: 2074-2084.
25. Robben JH, Sze M, Knoers N, Deen PMT. Functional rescue of vasopressin V2 receptor mutants in mdck cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2007; 292: F253-F260.
26. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; the SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
27. Farmakis D, Filippatos G, Kremastinos D, Gheorghiade M. Vasopressin and vasopressin antagonists in heart failure and hyponatremia. Curr Heart Fail Rep 2008; 5: 91-96.
28. Robben JH, Kortenoeven MLA, Sze M, Yae C, Milligan G, Oorschot V, Klumperman J, Knoers NVAM, Deen PMT. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci USA 2009; 106: 12195-12200.
29. Jean-Alphonse F, Perkovska S, Frantz MC, Durroux T, Mejean C, Morin D, Loison S, Bonnet D, Hibert M, Mouillac B, Mendre C. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 2009; 20: 2190-2203.
30. Noorwez SM, Malhotra R, McDowell JH, Smith KA, Krebs MP, Kaushal S. Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. J Biol Chem 2004; 279: 16278-16284.
31. Rus R, Haag C, Bumke-Vogt C, Bahr V, Mayr B, Mohlig M, Schulze E, Frank-Raue K, Raue F, Schofl C. Novel inactivating mutations of the calcium- sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors. J Clin Endocrinol Metab 2008; 93: 4797-4803.
32. Conn PM, Ulloa-Aguirre A, Ito J, Janovick JA. G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacol Rev 2007; 59: 225-250.
33. Janovick JA, Goulet M, Bush E, Greer J, Wettlaufer DG, Conn PM. Structure- activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropinreleasing hormone receptor. J Pharmacol Exp Ther 2003; 305: 608-614.
34. Dupre DJ, Baragli A, Rebois RV, Ethier N, Hebert TE. Signalling complexes associated with adenylyl cyclase II are assembled during their biosynthesis. Cell Signal 2007; 19: 481-489.
35. Dupre DJ, Robitaille M, Ethier N, Villeneuve LR, Mamarbachi AM, Hebert TE. Seven transmembrane receptor core signaling complexes are assembled prior to plasma membrane trafficking. J Biol Chem 2006; 281: 34561-34573.
36. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-1630.